Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of WCK 5222 in Renal Impairment
NCT02942810Phase 1Completed
- Sponsor
- Wockhardt
- Start
- Oct 2016
- Primary completion
- Apr 2017
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cefepime + zidebactam in gram-negative bacterial infections, sponsored by Wockhardt. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve. Started Oct 2016; status: completed.
02
Drugs
cefepime + zidebactam
03
Conditions
gram-negative bacterial infections
Beyond the preview
Go deeper on NCT02942810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02942810.